Even in non-small-cell lung cancer (NSCLC) where considerable efforts have been made to develop PD-L1 expression as a companion biomarker, most patients with PD-L1+ tumors are non-responders, while some patients with PD-L1- tumors do have durable response to ICI2. This evidence concerns the gene CD274 and non-small cell lung carcinoma.